Detection of E119V and E119I Mutations in Influenza A (H3N2) Viruses Isolated from an Immunocompromised Patient: Challenges in Diagnosis of Oseltamivir Resistance

被引:75
作者
Okomo-Adhiambo, Margaret [1 ]
Demmler-Harrison, Gail J. [2 ,3 ,4 ]
Deyde, Varough M. [1 ]
Sheu, Tiffany G. [1 ]
Xu, Xiyan [1 ]
Klimov, Alexander I. [1 ]
Gubareva, Larisa V. [1 ]
机构
[1] Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA
[2] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[4] Texas Childrens Hosp, Diagnost Virol Lab, Houston, TX 77030 USA
关键词
NEURAMINIDASE INHIBITORS; SUSCEPTIBILITY; ZANAMIVIR; SURVEILLANCE; WORLDWIDE; SELECTION; ASSAY;
D O I
10.1128/AAC.01608-09
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The clinical use of the neuraminidase inhibitor (NAI) oseltamivir is associated with the emergence of drug resistance resulting from subtype-specific neuraminidase (NA) mutations. The influenza A/Texas/12/2007 (H3N2) virus isolated from an oseltamivir-treated immunocompromised patient exhibited reduced susceptibility to oseltamivir in the chemiluminescent neuraminidase inhibition (NI) assay (similar to 60-fold increase in its 50% inhibitory concentration [IC50] compared to that for a control virus). When further propagated in cell culture, the isolate maintained reduced susceptibility to oseltamivir in both chemiluminescent and fluorescent NI assays (similar to 50-and 350-fold increases in IC50, respectively). Sequencing analysis of the isolate revealed a mix of nucleotides coding for amino acids at position 119 of the NA [E119(V/I)]. Plaque purification of the isolate yielded E119V and E119I variants, both exhibiting reduced susceptibility to oseltamivir. The E119I variant also showed decreased susceptibility to zanamivir and the investigational NAIs peramivir and A-315675. The emergence of E119V variants in oseltamivir-treated patients has been previously reported; however, the E119I mutation detected here is a novel one which reduces susceptibility to several NAIs. Both mutations were not detected in unpropagated original clinical specimens using either conventional sequencing or pyrosequencing, suggesting that these variants were present in very low proportions (<10%) in clinical specimens and gained dominance after virus propagation in MDCK cells. All virus isolates recovered from the patient were resistant to adamantanes. Our findings highlight the potential for emergence and persistence of multidrug-resistant influenza viruses in oseltamivir-treated immunocompromised subjects and also highlight challenges for drug resistance diagnosis due to the genetic instability of the virus population upon propagation in cell culture.
引用
收藏
页码:1834 / 1841
页数:8
相关论文
共 40 条
[1]   A Novel Neuraminidase Deletion Mutation Conferring Resistance to Oseltamivir in Clinical Influenza A/H3N2 Virus [J].
Abed, Yacine ;
Baz, Mariana ;
Boivin, Guy .
JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (02) :180-183
[2]  
Aoki FY, 2007, ANTIVIR THER, V12, P603
[3]   Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies [J].
Barnett, JM ;
Cadman, A ;
Gor, D ;
Dempsey, M ;
Walters, M ;
Candlin, A ;
Tisdale, M ;
Morley, PJ ;
Owens, IJ ;
Fenton, RJ ;
Lewis, AP ;
Claas, ECJ ;
Rimmelzwaan, GF ;
De Groot, R ;
Osterhaus, ADME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :78-87
[4]   Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an Immunocompromised child [J].
Baz, Mariana ;
Abed, Yacine ;
McDonald, Jane ;
Boivin, Guy .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (12) :1555-1561
[5]   Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern [J].
Bright, RA ;
Medina, MJ ;
Xu, XY ;
Perez-Oronoz, G ;
Wallis, TR ;
Davis, XHM ;
Povinelli, L ;
Cox, NJ ;
Klimov, AI .
LANCET, 2005, 366 (9492) :1175-1181
[6]   Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir [J].
Buxton, RC ;
Edwards, B ;
Juo, RR ;
Voyta, JC ;
Tisdale, M ;
Bethell, RC .
ANALYTICAL BIOCHEMISTRY, 2000, 280 (02) :291-300
[7]   Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo [J].
Carr, J ;
Ives, J ;
Kelly, L ;
Lambkin, R ;
Oxford, J ;
Mendel, D ;
Tai, L ;
Roberts, N .
ANTIVIRAL RESEARCH, 2002, 54 (02) :79-88
[8]  
Colacino Joseph M., 1997, Journal of Infectious Diseases, V176, pS66, DOI 10.1086/514179
[9]  
Colman P M, 2005, Expert Rev Anti Infect Ther, V3, P191, DOI 10.1586/14787210.3.2.191
[10]   STRUCTURE OF THE CATALYTIC AND ANTIGENIC SITES IN INFLUENZA-VIRUS NEURAMINIDASE [J].
COLMAN, PM ;
VARGHESE, JN ;
LAVER, WG .
NATURE, 1983, 303 (5912) :41-44